课题基金 / 基金详情

The Epileptogenic Effect of Perinatal Hypoxia

The Epileptogenic Effect of Perinatal Hypoxia
围产期缺氧的致癫痫作用
批准号:
8739994
负责人:
Frances E Jensen
金额:
$48.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-08-01 至 2016-09-29
关键词:

项目摘要

项目成果

Frances E Jensen的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):整个生命周期中癫痫发作的最高发生率发生在新生儿期,早期癫痫发作与以后的癫痫以及显著的神经认知和行为缺陷有关。我们之前的研究表明,兴奋性谷氨酸受体的α -氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(AMPAR)亚型在整个新生儿时期在啮齿动物和人类大脑中高度表达,并且是后期癫痫和行为合并症的关键介质。这个
英文摘要
DESCRIPTION (provided by applicant): The highest incidence of seizures across the lifespan occurs in the neonatal period, and seizures in early life are associated with later life epilepsy, and significant neurocognitive and behavioral deficits. Our prior studies have shown that the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPAR) subtype of the excitatory glutamate receptor is highly expressed in the rodent and human brain throughout the neonatal period, and is a critical mediator of the later epilepsy and behavioral comorbidities. The present proposal extends these studies and provides better preclinical assay systems for analysis of epileptogenesis and neurobehavior in both the rat and mouse model (Aim 1). We aim to better understand the mechanisms of seizure-induced alterations in network plasticity in order to identify reversible changes (Aim 2). Thus, we will extend our studies on the consequences of seizure-induced modifications of mammalian target of rapamycin (TOR) and Fragile X mental retardation protein (FMRP) pathways, and investigate the extent that brief pharmacologic manipulation of these pathways will decrease later life epilepsy and neurobehavioral deficits (Aim 3). Finally, we will study human tissue to determine whether there is evidence of dysregulation of AMPARs, mTOR or FMRP pathways in human brain tissue from neonates and infants with epilepsy (Aim 4). The overall goal of this ongoing research program is to identify mechanisms whereby this common form of seizures may induce later life epilepsy, cognitive and neurobehavioral deficits, including autism. The emphasis is on identifying therapeutic targets, preclinical disease modifying trials with clinically relevant outcomes, and validating these targets in human tissue to pave the way for translation clinical investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Seizure-induced enhancement of synaptic signaling regulating tau transmissibility in Alzheimer's Disease
  • 批准号:
    10611518
  • 项目类别:
  • 资助金额:
    $72.06万
  • 财政年份:
    2022
  • 负责人:
    Frances E Jensen
  • 依托单位:
Seizure-induced enhancement of synaptic signaling regulating tau transmissibility in Alzheimer's Disease
  • 批准号:
    10455852
  • 项目类别:
  • 资助金额:
    $67.4万
  • 财政年份:
    2022
  • 负责人:
    Frances E Jensen
  • 依托单位:
The NKCC1 inhibitor bumetanide as a novel therapy in TSC
  • 批准号:
    8457417
  • 项目类别:
  • 资助金额:
    $24.97万
  • 财政年份:
    2012
  • 负责人:
    Frances E Jensen
  • 依托单位:
The NKCC1 inhibitor bumetanide as a novel therapy in TSC
  • 批准号:
    8554384
  • 项目类别:
  • 资助金额:
    $18.79万
  • 财政年份:
    2012
  • 负责人:
    Frances E Jensen
  • 依托单位:
海外基金